Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02799706
Other study ID # EORTC-1414
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 25, 2017
Est. completion date June 2024

Study information

Verified date March 2023
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the trial is to assess if GnRH antagonists in combination with external beam radiation therapy improve progression free survival (progression that can be biological, clinical, or death) compared to GnRH agonists in combination with external beam radiation therapy. Secondary objectives include: - documentation of effect of GnRH antagonists on clinically significant cardiovascular events in the subgroup of patients at high risk of such events at baseline; - documentation of side effects and quality of life, I-PSS and urinary tract infections; - assessment of relative treatment effect on secondary efficacy endpoints (clinical progression, time to next line of systemic therapy, time on therapy, overall and cancer specific survival) and on PSA at 6 months after end of RT.


Description:

Phase IIIb randomized stratified open-label comparative 2-arm superiority study with a pre-set non-inferiority boundary. Registered GnRH antagonists, degarelix, will be given at the dose of 240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL on day 1, followed by 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL every 28 days (±2 days). External beam radiotherapy (EBRT) to a total dose of 78-80 Gy, delivered as one daily fraction, five days a week, started between d1 and months 6 of the androgen deprivation therapy as per institution policy. The irradiation is the same as in the reference therapy arm. The minimum duration of androgen deprivation with GnRH agonist or antagonist therapy is 18 months. For each patient, the duration of therapy must be elected upfront by the treating physician among three possible options: 18, 24 or 36 months. The institution shall also declare upfront the duration of the neoadjuvant treatment they intend to deliver to each patient (between 0 and 6 months). The primary endpoint is progression-free survival defined as the time in days from randomization to death, clinical or biochemical progression, whichever comes first. Where - PSA progression based on Phoenix definition, i.e. a rise by 2 ng/mL or more above the nadir PSA (Ref. 17) confirmed by a second value measured minimum 3 months later - Clinical progression is defined as onset of obstructive symptoms requiring local treatment and demonstrated to be caused by cancer progression or evidence of metastases detected by clinical symptoms and confirmed by imaging - Start of another line of systemic therapy in absence of progression - Death due to any cause Secondary endpoints: - Clinical progression-free survival - Time to next systemic anticancer therapy (including secondary hormonal manipulation) - Proportion of patients switching from GnRH antagonists to GnRH agonists and total effective duration of treatment with the originally allocated drug. - Overall survival - Cancer specific survival - PSA at six months after completion of RT Safety will be scored by the CTCAE version 4.0. The major safety endpoints in this study are - the incidence of clinical cardiovascular events - CCE (i.e. arterial embolic or thrombotic events, hemorrhagic or ischemic cerebrovascular conditions, myocardial infarction, and other ischemic heart disease) in patients who had cardiovascular events before entering the trial and in those without such events. - Incidence of urinary tract infection


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 885
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Histologically confirmed diagnosis of prostate adenocarcinoma - PSA = 10 ng/ml and two of the following 4 criteria: - PSA = 20 ng/ml, - Gleason sum = 8, - cN1 (regional LN with a short axis length >10mm by CT scan or MRI) or pathologically confirmed lymph nodes (pN1), - cT3-T4 (by MRI or core biopsy) (i.e. If PSA= 20 ng/ml then only one of the other 3 risk factors is needed) - M0 by standard imaging work-up (see chapter 6.1.1.1) - Testosterone = 200 ng/dl - Adequate renal function: calculated creatinine clearance = 50 mL/min (Appendix D) Magnesium and potassium within normal limits of the institution or corrected to within normal limits prior to the first dose of treatment. - Patients with prolonged QT-intervals due to prescribed Class IA (quinidine, procainamide) or Class III (amiodarone, sotalol) antiarrhythmic medication must be carefully evaluated for GnRH-agonist or GnRH antagonist use, because these drugs may prolong the QT-interval. - WHO Performance status 0-1 - Age = 18 and = 80 years - Participants who have partners of childbearing potential must use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 3 months after last dose of study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly - Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations. Exclusion Criteria: - Previous use of androgen deprivation therapy (ADT), antiandrogens. 5-alpha reductase inhibitors are allowed if interrupted for more than 6 months prior to entering the study - History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema. - Hypersensitivity towards the investigational drug - The following biological parameters :AST, ALT, total bilirubin, prothrombin time, serum albumin above upper level of normal range No severe hepatic impairment (Child Pugh C) - History of gastro-intestinal disorders (medical disorder or extensive surgery) that may interfere with the absorption of the protocol treatment. - History of pituitary or adrenal dysfunction - Uncontrolled diabetes mellitus - History of ulcerative colitis, Crohn's Disease, ataxia, telangiectasia, systemic lupus erythematous, or Fanconi anemia. - Clinically significant heart disease as evidence myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class III or IV heart disease or cardiac ejection fraction measurement of < 50 % at baseline - Coronary revascularization (PCI or multivessel CABG), carotid artery or iliofemoral artery revascularization (percutaneous or surgical procedure) within the last 30 days prior to entering the trial - Certain risk factors for abnormal heart rhythms/QT prolongation: torsade de pointes ventricular arrhythmias (e.g, heart failure, hypokalemia, or a family history of a long QT syndrome), a QT or corrected QT (QTc) interval >450 ms at baseline, or intake of medications that prolong the QT/QTc interval - Uncontrolled hypertension (systolic BP = 160 mmHg or diastolic BP = 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment. - Prior history of malignancies other than prostate adenocarcinoma (except patients with basal cell, squamous cell carcinoma of the skin), or the patient has been free of malignancy for a period of 3 years prior to first dose of study drug(s). Prior history of bladder cancer excludes the patient. - Prior radical prostatectomy (TURP or suprapubic adenomectomy for benign prostatic hyperplasia is allowed) - Prior brachytherapy or other radiotherapy that would result in an overlap of radiotherapy fields - Any contraindication to external beam radiotherapy - Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule or any condition which, in the opinion of the investigator, would preclude participation in this trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Degarelix
a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
approved GnRH agonist
A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
Radiation:
Radiotherapy
.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)

Locations

Country Name City State
Belgium Universitair Ziekenhuis Brussel Brussel
Belgium Cliniques Universitaires Saint-Luc Brussels
Belgium Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme Brussels
Belgium Hopitaux Universitaires Bordet-Erasme - Hopitaux Universitaires Bordet- Institut Jules Bordet Brussels
Belgium Hopital De Jolimont Haine-Saint-Paul
Belgium AZ Groeninge Kortrijk - Campus Kennedylaan Kortrijk
Belgium CHU Ucl Namur - Site Sainte-Elisabeth Namur
Belgium Gasthuiszusters van Antwerpen - GasthuisZusters Antwerpen - Sint-Augustinus Wilrijk
Denmark University Hospitals Copenhagen - Rigshospitalet Copenhagen
France Clinique de l'Europe Amiens
France Centre de radiotherapie Marie Curie Arras
France Centre D'Onco. & Radioth. De Haute Energie Du Pays Basque Bayonne
France Groupe Radiopole Artois - Centre de Radiotherapie Pierre Curie Beuvry
France CHU de Grenoble - La Tronche - Hôpital A. Michallon Grenoble
France Centre Leon Berard Lyon
France Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau Nantes
France Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere Paris
France Centre Hospitalier Privé Saint-Grégoire Saint-Gregoire
France Clinique Pasteur-Toulouse-Atrium Toulouse
Germany Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin Berlin
Germany Universitaetsklinikum Freiburg Freiburg
Germany Otto-Von-Guericke-Universitaet Magdeburg - Universitaetsklinik Magdeburg
Italy Azienda Ospedaliero-Universitaria Careggi Firenze
Italy AUSL Romagna - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Meldola
Spain Fundacion Hospital Alcorcon Alcorcón
Spain Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) Barcelona
Spain Clinica IMQ Zorrotzaurre Bilbao
Spain Hospital General Universitario Santa Lucia Cartagena
Spain Hospital Universitario Reina Sofia Córdoba
Spain Hospital Universitario de Gran Canaria Doctor Negrin Las Palmas De Gran Canaria
Spain Complejo Hospitalario A Pamplona
Spain Corporacio Sanitaria Parc Tauli Sabadell
Spain Hospital Universitario de Salamanca Salamanca
Spain Hospital Consorci Sanitari De Terrassa Terrassa
Spain Complejo Hospitalario Universitario de Vigo -CHUVI - Hospital Alvaro Cunqueiro Vigo
Switzerland Oncology Institute of Southern Switzerland (IOSI) - Oncology Institute of Southern Switzerland - Ospedale Regionale Bellinzona e Valli Bellinzona
Switzerland Inselspital Bern
Switzerland Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie Geneve
United Kingdom Nottingham University Hospitals NHS Trust - City Hospital Nottingham

Sponsors (1)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Countries where clinical trial is conducted

Belgium,  Denmark,  France,  Germany,  Italy,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival The primary endpoint is progression-free survival defined as the time in days from randomization to death, clinical or biochemical progression, whichever comes first.
Where
PSA progression based on Phoenix definition, i.e. a rise by 2 ng/mL or more above the nadir PSA (Ref. 17) confirmed by a second value measured minimum 3 months later
Clinical progression is defined as onset of obstructive symptoms requiring local treatment and demonstrated to be caused by cancer progression or evidence of metastases detected by clinical symptoms and confirmed by imaging
Start of another line of systemic therapy in absence of progression
Death due to any cause
through study completion, an average of 1 year
Secondary Clinical progression-free survival through study completion, an average of 1 year
Secondary Time to next systemic anticancer therapy (including secondary hormonal manipulation) through study completion, an average of 1 year
Secondary ? Proportion of patients switching from GnRH antagonists to GnRH agonists through study completion, an average of 1 year
Secondary ? Overall survival through study completion, an average of 1 year
Secondary Incidence of clinical cardiovascular events ? the incidence of clinical cardiovascular events - CCE (i.e. arterial embolic or thrombotic events, hemorrhagic or ischemic cerebrovascular conditions, myocardial infarction, and other ischemic heart disease) in patients who had cardiovascular events before entering the trial and in those without such events. through study completion, an average of 1 year
Secondary ? Incidence of urinary tract infection through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A